tbuckley/cabot-search huggingface dataset:
Radiation therapy for rectosigmoid and rectal cancer: results of the 1992-1994 Patterns of Care process survey.
Authors: B D Minsky, L Coia, D G Haller, J Hoffman, M John, J Landry, T M Pisansky, C Willett, I Mahon, J Owen, B Berkey, A Katz, G Hanks
Journal: Journal of Clinical Oncology (1998)

PURPOSE To determine the US national practice standards for patients with adenocarcinoma of the rectum treated in radiation oncology facilities. MATERIALS AND METHODS A national survey of 57 institutions identified 507 eligible patients who received radiation therapy as a component of their treatment for rectal cancer. A stratified two-stage cluster sampling with simple random sampling at each stage for each stratum was used and on-site surveys were performed. RESULTS Of the 507 patients, 378 (75%) received postoperative therapy, 110 (22%) received preoperative therapy, 17 (2%) received both preoperative and postoperative therapy, and less than 0.5% received intraoperative radiation alone. To more accurately assess the utilization of modern radiation techniques as well as recommendations of the National Cancer Institute (NCI)-sponsored, randomized, postoperative, adjuvant combined modality therapy rectal cancer trials into current practice, the analysis was limited to the 243 (48%) patients with tumor, node, and metastasis staging system classification T3 and/or N1-2M0 disease who underwent conventional surgery with negative margins. Although only 7% were treated on a clinical trial, 90% received chemotherapy for a median of 21 weeks. Most were treated with modern radiation treatment techniques. In contrast, techniques to identify and help exclude the small bowel from the radiation field were not routinely used. CONCLUSION Despite the fact that only 7% of patients with T3 and/or N1-2M0 disease were treated on a clinical trial, such trials appear to have resulted in a positive influence on the standard of practice within the oncology community. Although there are still some deficiencies, the majority of these patients received combined modality therapy and were treated with modern radiation therapy techniques.
A phase I pharmacokinetic (PK) study of the Epothilone B analogue, ixabepilone (BMS-247550) in patients (pts) with advanced malignancies and varying degrees of hepatic impairment. A SWOG Early Therapeutics Committee and NCI Organ Dysfunction Working Group Trial
Authors: C. H. Takimoto, P. Y. Liu, H. Lenz, S. Remick, D. Mulkerin, S. Mani, T. W. Synold, R. K. Ramanathan, P. Ivy, A. M. Davies
Journal: Journal of Clinical Oncology (2006)

2004 Background: Ixabepilone (Ix) is a semisynthetic Epothilone B derivative with antitumor activity in breast cancer pts previously treated with taxanes and in chemotherapy naïve prostate cancer pts. Because Ix is hepatically metabolized, the following study was performed to define dosing recommendations for pts with varying degrees of hepatic impairment. Methods: Pts were classified into hepatic dysfunction cohorts defined by a modified NCI Organ Dysfunction Working Group (NCI) schema. Starting doses were escalated in new pts independently in each cohort using a standard phase I design. Results: Overall, 71 pts were registered and 66 pts are evaluable for cycle 1 dose limiting toxicities (DLTs). Ix was administered at 10–40 mg/m 2 as 10 minute infusions q3wks. Dose levels reached 40, 40, 30, and 20 mg/m 2 for pts in Groups A, B, C and D, respectively. In group B, DLTs were observed in 2/12 pts treated at 30 mg/m 2 (febrile neutropenia, grade (gr)3 mucositis, and gr3 diarrhea) and 3/8 pts at 40 mg/m 2 (febrile neutropenia, gr3 nausea/vomiting, gr3 hyponatremia). In group C, DLTs were observed in 2/10 pts at 20 mg/m 2 (gr3 dehydration, gr3 muscle weakness) and 2/3 pts at 30 mg/m 2 (febrile neutropenia, gr 4 neutropenia). In group D, DLTs were observed in 2/9 pts at 10 mg/m 2 (gr3 infection and gr3 renal failure) and 1/5 pts treated at 20 mg/m 2 (gr3 infection). Otherwise, Ix was generally well tolerated. Pharmacokinetic parameters are currently being analyzed. No objective responses have been documented. Conclusions: Ix dose reduction is required in pts with moderate to severe liver dysfunction. The recommended Ix dose for group C patients is 30 mg/m 2 . To define the impact of mild liver impairment, Group B has been stratified further into B1 (Bili ≤ ULN and AST &gt; ULN) and B2 (ULN &lt; Bili ≤ 1.5 × ULN, AST any). Accrual continues to groups B1 and B2 at 40 mg/m 2 and group D at 20 mg/m 2 . [Table: see text] [Table: see text]
Epidemiology of Cancer of the Pancreas2
Authors: Ernest L. Wynder, Kiyohiko Mabuchi, Nobuhiro Maruchi, Joseph G. Fortner
Journal: JNCI Journal of the National Cancer Institute (1973)

Journal Article Epidemiology of Cancer of the Pancreas Get access Ernest L. Wynder, M.D., Ernest L. Wynder, M.D. * Naylor Dana Research Institute for Disease Prevention, American Health Foundationl New York, New York 100211 and The Department of Gastric and Mixed Tumors, Memorial Hospital for Cancer and Allied Diseases, New York, New York 10021 *Address reprint requests to: Dr. E. L. Wynder, American Health Foundation, 1370 Ave. of the Americas, New York, N.Y. 10019. Search for other works by this author on: Oxford Academic PubMed Google Scholar Kiyohiko Mabuchi, M.D., Kiyohiko Mabuchi, M.D. Naylor Dana Research Institute for Disease Prevention, American Health Foundationl New York, New York 100211 and The Department of Gastric and Mixed Tumors, Memorial Hospital for Cancer and Allied Diseases, New York, New York 10021 Search for other works by this author on: Oxford Academic PubMed Google Scholar Nobuhiro Maruchi, M.D., D.M.Sc., Nobuhiro Maruchi, M.D., D.M.Sc. Naylor Dana Research Institute for Disease Prevention, American Health Foundationl New York, New York 100211 and The Department of Gastric and Mixed Tumors, Memorial Hospital for Cancer and Allied Diseases, New York, New York 10021 Search for other works by this author on: Oxford Academic PubMed Google Scholar Joseph G. Fortner, M.D. Joseph G. Fortner, M.D. Naylor Dana Research Institute for Disease Prevention, American Health Foundationl New York, New York 100211 and The Department of Gastric and Mixed Tumors, Memorial Hospital for Cancer and Allied Diseases, New York, New York 10021 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 50, Issue 3, March 1973, Pages 645–667, https://doi.org/10.1093/jnci/50.3.645 Published: 01 March 1973 Article history Received: 28 July 1972 Accepted: 07 November 1972 Published: 01 March 1973
Mediterranean Diet and Its Association With Reduced Invasive Breast Cancer Risk
Authors: Franco Berrino
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
P-glycoprotein (p-gp) expression and function as an independent prognostic factor in childhood acute lymphoblastic leukemia
Authors: P. Indolfi, F. Casale, V. D'Angelo, R. Addeo, S. Crisci, E. Pota, M. T. Di Tullio
Journal: Journal of Clinical Oncology (2004)

8503 Background: Little is known about the prognostic role of multidrug resistance (MDR) in newly diagnosed childhood with acute lymphoblastic leukemia (ALL). The aim of this retrospective study was to evaluate in 85 children with ALL the impact of P-glycoprotein 170 (p-gp) product of the mdr-1 gene on achievement of complete remission (CR), and clinical outcome. Methods: MDR-1 protein expression was performed by immunocytochemistry (ICC), and flow cytometry (FC). MDR-1 functional activity was performed by rhodamine (Rhd)-123 efflux test with or without verapamil. All patients enrolled in our study were treated with AIEOP 91–95 protocols. Results: Forty patients (47%) expressed MDR1 protein at significant levels, and 45 (53%) were MDR1 negative. Forty-three of the last patients were also negative for MDR1 function, while 34 out of 40 (85%) patients MDR-1 positive preserved the function. Rhd-123 efflux was inhibited by the MDR modulator verapamil in 12 of 40 (30%) patients. After induction treatment, CR was achieved in 77/85 children (90.6%). All patients who didn't achieved CR were MDR positive. Twenty-nine patients relapsed, and 17 of these (58.6%) were MDR-positive.. The 10-year event-free survival (EFS) rate was significantly higher (67.5% vs 36.8%) in the p-gp negative group compared with the p-gp positive population (p=0.001). Multivariate analysis showed the results to be indipendent of age, WBC count, immunophenotype, FAB classification, and prednisone response (p=0.019). The 10-year overall survival (OS) rate, and disease-free survival (DFS) for p-gp negative patients compared to p-gp positive patients were 75.7% vs 54.8%, and 67.5% vs 46%, respectively. Conclusions: Our results demonstrate that MDR1 expression and function in childhood with ALL are an independent prognostic factor of worse outcome and could be an useful biological marker of response in these patients. No significant financial relationships to disclose.
Abstract 5424: Therapeutic targeting of KRAS mutation-driven tumor progression in colorectal cancer
Authors: Christina Wu, Peng-Chan Lin, Po-Chen Chu, Hsiao-Ching Chuang, Samuel Kulp, Tanios Bekaii-Saab, Ching-Shih Chen
Journal: Cancer Research (2015)

Abstract KRAS is the most frequently altered gene in colorectal cancer (CRC), with mutations occurring in 30-40% of colorectal cancer. Although KRAS mutation is associated with poor prognosis and resistance to anti-epidermal growth factor receptor therapy, the mechanism by which it promotes tumor metastasis remains undefined. Our study explored a new hypothesis that targeting the Y-box binding protein-1 (YB-1)-insulin-like growth factor-I receptor (IGF-IR) signaling axis which is downstream of KRAS, with a novel integrin-linked kinase inhibitor, T315, represents a therapeutically relevant strategy to block KRAS mutation-driven tumor progression. In liver metastases from CRC patients, we observed that there was a preponderance (79/108) of over-expression in both YB-1 and IGF-1R by immunohistochemistry. In colon cancer cell lines HCT-116 and SW480, knockdown and over-expression of KRAS affected the protein and mRNA levels of IGF-1R in a dose-dependent manner. But KRAS only affected the protein level and not mRNA of YB-1, thus suggesting that KRAS regulated YB-1 expression at the post-transcriptional level. Manipulation of YB-1 via plasmid overexpression and siRNA affected IGF-1R protein and mRNA levels in a dose-dependent manner, and YB-1 and IGF-1R promoter binding was confirmed via ChIP assay. There was a dose-dependent decrease in YB-1 and IGF-1R protein levels with MEK162, a MEK inhibitor, but not with LY294002m a PI3K inhibitor. This demonstrated that the KRAS regulation of the YB-1- IGFR-1R signaling axis to be via the MEK signaling pathway and not PI3K/Akt. Our novel drug T315 targets YB-1, and was shown to inhibit cell viability and cell migration in a dose-dependent manner. T315 treatment of the colon cancer cells also decreased protein levels of YB-1 and IGF-1R and affected epidermal mesenchymal transition markers such as E-cadherin, vimentin, and snail. These results suggest that a combination of a MEK inhibitor and T315 may be an effective therapeutic strategy to target KRAS mutation driven CRC. Citation Format: Christina Wu, Peng-Chan Lin, Po-Chen Chu, Hsiao-Ching Chuang, Samuel Kulp, Tanios Bekaii-Saab, Ching-Shih Chen. Therapeutic targeting of KRAS mutation-driven tumor progression in colorectal cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 5424. doi:10.1158/1538-7445.AM2015-5424
The American Board of Internal Medicine recertification program: nearing liftoff.
Authors: W G Johanson
Journal: Journal of Clinical Oncology (1995)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1995.13.7.1831 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 7602377 The American Board of Internal Medicine recertification program: nearing liftoff. W G JohansonxW G JohansonSearch for articles by this author https://doi.org/10.1200/JCO.1995.13.7.1831 PDF "The American Board of Internal Medicine recertification program: nearing liftoff.." Journal of Clinical Oncology, 13(7), pp. 1831–1832© 1995 by American Society of Clinical Oncology
NHS figures indicate variation in readmission rate among patients discharged at weekends
Authors: Gareth Iacobucci
Journal: BMJ (2016)

The likelihood of emergency readmission to hospital within seven days of discharge may be higher among patients discharged at weekends, new figures for England indicate, though further analysis would be needed to establish a trend, if any.

Experimental figures published by the Health and Social Care Information Centre show that the proportion of emergency readmissions within seven days of discharge was 3.2% among patients discharged on Monday, Tuesday, and Wednesday but 4.9% among those discharged on Sunday.1 The rates were 3.3% on Thursdays, 3.5% on Fridays, and 4.1% on Saturdays. …
Long-term survival in patients with metastatic melanoma vaccinated with melanoma-antigen loaded dendritic cells
Authors: J. W. Fay, J. Banchereau, K. Palucka
Journal: Journal of Clinical Oncology (2007)

8547 Background: Previous clinical trials have demonstrated safety and tolerability of cancer antigen-loaded dendritic cells (DCs) in the treatment of metastatic melanoma. Further, DCs administered to patients with metastatic melanoma are immunogenic and induce durable clinical responses even in patients who failed previous cytotoxic therapy. This report is an analysis of long term clinical outcomes of DC vaccinated patients from our institution. Methods: Between March 1999 and February 2005 seventy patients with metastatic melanoma were treated with DC vaccines in four sequential phase I-IIa clinical trials. Most patients had M1b or M1c metastatic disease. DCs were generated either from CD34+ hematopoietic progenitors or from monocytes. Forty nine HLA-A*0201 + patients received vaccines pulsed with melanoma antigen derived peptides (MART-1, MAGE-3, TYR and gp100). Twenty one patients received DCs loaded with killed allogeneic melanoma cells. KLH was used as helper antigen and, in HLA-A*0201 + patients, Flu-Matrix peptide was used as control antigen. Patients received up to eight DC vaccinations over a maximum of 7 months. Results: DC vaccinations were safe and tolerable. Fifteen out of 70 (21%) patients are alive as of November 2006. The median survival in this group of surviving patients is 46 months (range 22–92 months). Three patients had no evidence of disease upon completion of DC vaccinations by clinical and positron emission tomography scanning. Four patients had experienced objective clinical responses by RECIST criteria (2 CRs and 2 PRs) based on clinical examination and computerized tomography or magnetic resonance imaging. These included two patients that had failed previous cytotoxic and cytokine therapy. Eight patients are alive with disease. Five of 15 long term survivors had no additional therapy other than DC vaccinations including a patient with CR of liver lesions who remains free of disease 80 months post DC vaccination. Conclusions: DC vaccines bring clinical benefit and elicit durable responses in a fraction of patients with metastatic melanoma. These vaccines may provide a survival advantage. Future studies are underway to improve DC vaccine efficacy for treatment of metastatic melanoma. No significant financial relationships to disclose.
Relative Wall Thickness and the Risk for Ventricular Tachyarrhythmias in Patients With Left Ventricular Dysfunction
Authors: Yitschak Biton, Ilan Goldenberg, Valentina Kutyifa, Jayson R. Baman, Scott Solomon, Arthur J. Moss, Barbara Szepietowska, Scott McNitt, Bronislava Polonsky, Wojciech Zareba, Alon Barsheshet
Journal: Journal of the American College of Cardiology (2016)
Abstract 15134: Myocardial Restoration of Casq2 Protein in Adult Casq2 Null Mice Reverses Myocyte Remodeling and Completely Prevents CPVT Phenotype
Authors: Michela Faggioni, Ramesh V Iyer, Marcelo Baldo, Aditya Shirali, Cameron Johnson, Matthew Van Winkle, Clara Franzini-Armstrong, Sabine Huke, Karl Pfeifer, Bjorn C Knollmann
Journal: Circulation (2013)

Background:  Casq2 null mutations cause a recessive arrhythmia disorder known as catecholaminergic polymorphic ventricular tachycardia (CPVT). Casq2 null mouse myocytes show structural remodeling (ie. sarcoplasmic reticulum (SR) remodeling and near complete loss of triadin and junctin protein) that contributes to the arrhythmia risk. Casq2 viral gene transfer in neonatal Casq2 null mice can prevent structural remodeling and development of CPVT, but whether gene therapy is effective in adult mice with fully-established disease is not known.   Objective:  To test whether Casq2 restoration in adult Casq2 null mice can reverse myocyte remodeling and prevent CPVT.   Methods and Results:  To achieve complete restoration of Casq2 protein in the adult myocardium, we generated a “rescueable” Casq2 null allele, where treatment with Cre recombinase restores the wild-type Casq2 gene. Mice homozygous for this rescuable Casq2 null allele were crossed with mice expressing tamoxifen (TAM) inducible Cre in the heart (“rescue”). Before TAM treatment, 3-4 month old “rescue” Casq2 mice lack myocardial Casq2 protein (FIGURE) and exhibit a full-blown CPVT phenotype. 7 days after TAM, Casq2 protein expression reached wild-type levels and was homogeneously expressed throughout the heart (FIGURE). Triadin and junctin protein levels were restored. Electron microscopy showed normal-appearing junctional SR containing newly expressed Casq2. Restoration of Casq2 by TAM completed prevented ventricular arrhythmia (VA) during isoproterenol/caffeine challenge (8/12 with VA before TAM vs 0/12 after TAM, p   Conclusions:  Our results provide proof-of-concept that successful gene therapy in the adult can reverse myocardial remodeling and prevent arrhythmias in a mouse model of severe homozygous recessive CPVT.
Incidence of Dementia over Three Decades in the Framingham Heart Study
Authors: Claudia L. Satizabal, Alexa S. Beiser, Vincent Chouraki, Geneviève Chêne, Carole Dufouil, Sudha Seshadri
Journal: New England Journal of Medicine (2016)

The prevalence of dementia is expected to soar as the average life expectancy increases, but recent estimates suggest that the age-specific incidence of dementia is declining in high-income countries. Temporal trends are best derived through continuous monitoring of a population over a long period with the use of consistent diagnostic criteria. We describe temporal trends in the incidence of dementia over three decades among participants in the Framingham Heart Study.
Oral and extraoral plasmablastic lymphoma: Similarities and differences in clinicopathological characteristics.
Authors: A. Stefanovic, D. M. Hansra, N. Montague, I. Akunyili, A. Harzand, Y. Natkunam, M. de la Ossa, G. E. Byrne, I. S. Lossos
Journal: Journal of Clinical Oncology (2010)

e18539 Background: Plasmablastic lymphoma (PBL) was initially characterized as an aggressive subtype of NHL most frequently arising in the jaw and oral cavity in patients with HIV infection, accounting for 3% of all NHL in this patient population. Recent reports have described patients with PBL presenting with extraoral manifestations, heterogeneity in histologic findings, and variable association with immunodeficiency states. Methods: We reviewed the clinical, laboratory, morphological and immunophenotypic features of 16 cases of PBL seen at the University of Miami to determine whether these different subtypes represent distinct morphological and clinical entities. Results: Based on clinical presentation, two distinct subtypes of PBL were identified and classified as oral (n=7) and extraoral (n=9) PBL. Median patient age was 42.5 (range 4-73) with overall slight male predominance (9:7, ratio 1.3:1). The majority of patients presented with stage III or IV disease. Oral PBL was strongly associated with HIV infection and commonly demonstrated plasmablastic morphology without plasmacytic differentiation. Extraoral PBL involved bones, bone marrow, lymph nodes, nasopharynx, central nervous system, terminal ileum and cecum and tended to occur in patients with underlying non-HIV-related immunosuppression and universally demonstrated plasmacytic differentiation. Treatment was not standardized and included different combination chemotherapy regimens and radiotherapy. After a median follow-up of 16 months, eight of 14 treated patients have died and six are alive (four in remission and two with active disease). The median survival of all patients was 5.5 months (range 2-48). Patients with oral PBL demonstrated better overall survival (OS) compared to those with extraoral PBL (p=0.04). Conclusions: Our findings suggest that PBL with oral and extraoral presentations represent two distinct clinicopathologic entities. No significant financial relationships to disclose.